Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy-Reference-Cited by-同舟云学术

Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy

Published:2009-11 Issue:5 Volume:182 Page:2257-2264
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Bhoopalam Nirmala¹,Campbell Steven C.¹,Moritz Thomas¹,Broderick William R.¹,Iyer Padmini²,Arcenas Anthony G.³,Van Veldhuizen Peter J.⁴,Friedman Nicholas¹,Reda Domenic¹,Warren Stuart⁵,Garewal Harinder⁶

Affiliation:

1. Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois

2. Veterans Affairs Long Beach Healthcare System, Long Beach, California

3. Washington, D.C. Veterans Affairs Medical Center, Washington, D.C.

4. Kansas City Veterans Affairs, Kansas City, Missouri

5. Cooperative Studies Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico

6. Southern Arizona Veterans Affairs Healthcare System, Tucson, Arizona

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference24 articles.

1. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer;Ross;J Urol,2002

2. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens;Eriksson;Calc Tiss Int,1995

3. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostate carcinoma;Maillefert;J Urol,1999

4. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer;Smith;J Clin Oncol,2005

5. Risk of fracture after androgen deprivation for prostate cancer;Shahinian;N Engl J Med,2005

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer;Journal of Bone and Mineral Metabolism;2023-04-10

2. Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications;Cancers;2023-02-28

3. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis;Archives of Osteoporosis;2023-01-10

4. Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy;Japanese Journal of Clinical Oncology;2021-09-20

5. Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis;Supportive Care in Cancer;2021-08-15